WuXi AppTec Receives 2009 Lilly Global Supplier Award
May 05, 2009
May 5, 2009 – Shanghai, China – WuXi AppTec, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it had received the 2009 Lilly Global Supplier Award from Eli Lilly and Company.
"We are honored to receive this award and deeply appreciate Lilly's recognition of the talent and efforts of WuXi scientists," said Dr. Ge Li, Chairman and Chief Executive Officer. "The award reflects the depth of our commitment to Lilly and to all of our customers. We help them improve their R&D productivity by providing an integrated suite of high-quality drug discovery, development and manufacturing services in a timely and cost-effective manner. Our new GLP drug safety evaluation center in Suzhou and our expanded commercial manufacturing facility in the Jinshan area of Shanghai, both of which are fully constructed and undergoing validation, will further broaden our service portfolio."
Winners of this award are designated on the basis of their superior performance in helping the company maintain its competitive edge. WuXi was named a chemical product R&D preferred partner by Lilly in 2006.
About WuXi AppTec and WuXi PharmaTech
WuXi AppTec is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi AppTec is an operating subsidiary of WuXi PharmaTech traded under NYSE symbol WX, formally WuXi PharmaTech (Cayman) Inc. For more information, please visit: http://www.wuxiapptec.com.